Non coding RNA analysis in fibrolamellar hepatocellular carcinoma

Benjamin A. Farber, Gadi Lalazar, Elana P. Simon, William J. Hammond, David Requena, Umesh K. Bhanot, Michael P. La Quaglia, Sanford M. Simon

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary liver cancer found in adolescents and young adults without underlying liver disease. A deletion of ~400 kD has been found in one copy of chromosome 19 in the tumor tissue of all patients tested. This produces a fusion of the genes DNAJB1 and PRKACA which, in turn, produces a chimeric transcript and protein. Transcriptomic analysis of the tumor has shown upregulation of various oncologically relevant pathways, including EGF/ ErbB, Aurora Kinase A, pak21 and wnt. To explore other factors that may contribute to oncogenesis, we examined the microRNA (miRNA) and long non-coding RNA (lncRNA) expression in FLC. The non-coding RNA expression profile in tumor tissue samples is distinctly different from the adjacent normal liver and from other liver tumors. Furthermore, miRZip knock down or over expression of certain miRNAs led to changes in the levels of coding genes that recapitulated changes observed in FLC, suggesting mechanistically that the changes in the cellular levels of miRNA are not merely correlative. Thus, in addition to serving as diagnostic tools for FLC, non-coding RNAs may serve as therapeutic targets.

Original languageEnglish (US)
Pages (from-to)10211-10227
Number of pages17
JournalOncotarget
Volume9
Issue number12
DOIs
StatePublished - 2018
Externally publishedYes

Keywords

  • Fusion protein
  • Liver cancer
  • LncRNAs
  • MicroRNA
  • Pediatric cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Non coding RNA analysis in fibrolamellar hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this